Report Detail
Global (United States, European Union and China) Anti-Obesity Therapeutics Market Research Report 2019-2025
- RnM3685612 |
- 20 August, 2019 |
- Global |
- 119 Pages |
- QYResearch |
- Pharma & Healthcare
Anti-obesity drugs are the drugs that help in reducing or controlling body mass, either by decreasing the craving or increasing the consumption of calories. Appetite control is achieved through the use of agonists for appetite suppressing pathways.
Geographically, North America captures the largest market share on account of increasing obese population. As per the historical trends, more than one-third of the U.S. population is obese. However, Asia Pacific is anticipated to grow at the fastest rate due to increasing demand for the drugs and awareness about the risk associated with obesity. According to WHO, 13.0% of the population were obese in 2014. In developing countries the rate of childhood obesity is increasing and has been 30.0% higher than that of developed countries.
In 2019, the market size of Anti-Obesity Therapeutics is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Anti-Obesity Therapeutics.
This report studies the global market size of Anti-Obesity Therapeutics, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Anti-Obesity Therapeutics sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Bristol-Myers Squibb
Eisai Company
FlaxoSithKline plc.
Novo Nordisk
Alizyme
BoehringerIngelheim GmbH
Pfizer
Takeda Pharmaceutical
Rhythm Pharmaceuticals
Shionogi USA
Vivus
Zafgen
Norgine Pharmaceuticals Ltd.
Market Segment by Product Type
Centrally Acting Anti-obesity Drugs
Peripherally Acting Anti-obesity Drugs
Market Segment by Application
Hospital Use
Clinic Use
Household
Other
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Anti-Obesity Therapeutics status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Anti-Obesity Therapeutics manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Anti-Obesity Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Anti-Obesity Therapeutics Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Centrally Acting Anti-obesity Drugs
- 1.3.3 Peripherally Acting Anti-obesity Drugs
- 1.4 Market Segment by Application
- 1.4.1 Global Anti-Obesity Therapeutics Market Share by Application (2019-2025)
- 1.4.2 Hospital Use
- 1.4.3 Clinic Use
- 1.4.4 Household
- 1.4.5 Other
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Anti-Obesity Therapeutics Market Size
- 2.1.1 Global Anti-Obesity Therapeutics Revenue 2014-2025
- 2.1.2 Global Anti-Obesity Therapeutics Sales 2014-2025
- 2.2 Anti-Obesity Therapeutics Growth Rate by Regions
- 2.2.1 Global Anti-Obesity Therapeutics Sales by Regions 2014-2019
- 2.2.2 Global Anti-Obesity Therapeutics Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Anti-Obesity Therapeutics Sales by Manufacturers
- 3.1.1 Anti-Obesity Therapeutics Sales by Manufacturers 2014-2019
- 3.1.2 Anti-Obesity Therapeutics Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Anti-Obesity Therapeutics Revenue by Manufacturers (2014-2019)
- 3.2.2 Anti-Obesity Therapeutics Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Anti-Obesity Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.3 Anti-Obesity Therapeutics Price by Manufacturers
- 3.4 Key Manufacturers Anti-Obesity Therapeutics Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Anti-Obesity Therapeutics Market
- 3.6 Key Manufacturers Anti-Obesity Therapeutics Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Centrally Acting Anti-obesity Drugs Sales and Revenue (2014-2019)
- 4.1.2 Peripherally Acting Anti-obesity Drugs Sales and Revenue (2014-2019)
- 4.2 Global Anti-Obesity Therapeutics Sales Market Share by Type
- 4.3 Global Anti-Obesity Therapeutics Revenue Market Share by Type
- 4.4 Anti-Obesity Therapeutics Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Anti-Obesity Therapeutics Sales by Application
6 United States
- 6.1 United States Anti-Obesity Therapeutics Breakdown Data by Company
- 6.2 United States Anti-Obesity Therapeutics Breakdown Data by Type
- 6.3 United States Anti-Obesity Therapeutics Breakdown Data by Application
7 European Union
- 7.1 European Union Anti-Obesity Therapeutics Breakdown Data by Company
- 7.2 European Union Anti-Obesity Therapeutics Breakdown Data by Type
- 7.3 European Union Anti-Obesity Therapeutics Breakdown Data by Application
8 China
- 8.1 China Anti-Obesity Therapeutics Breakdown Data by Company
- 8.2 China Anti-Obesity Therapeutics Breakdown Data by Type
- 8.3 China Anti-Obesity Therapeutics Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Anti-Obesity Therapeutics Breakdown Data by Company
- 9.2 Rest of World Anti-Obesity Therapeutics Breakdown Data by Type
- 9.3 Rest of World Anti-Obesity Therapeutics Breakdown Data by Application
- 9.4 Rest of World Anti-Obesity Therapeutics Breakdown Data by Countries
- 9.4.1 Rest of World Anti-Obesity Therapeutics Sales by Countries
- 9.4.2 Rest of World Anti-Obesity Therapeutics Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Bristol-Myers Squibb
- 10.1.1 Bristol-Myers Squibb Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.1.4 Anti-Obesity Therapeutics Product Introduction
- 10.1.5 Bristol-Myers Squibb Recent Development
- 10.2 Eisai Company
- 10.2.1 Eisai Company Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.2.4 Anti-Obesity Therapeutics Product Introduction
- 10.2.5 Eisai Company Recent Development
- 10.3 FlaxoSithKline plc.
- 10.3.1 FlaxoSithKline plc. Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.3.4 Anti-Obesity Therapeutics Product Introduction
- 10.3.5 FlaxoSithKline plc. Recent Development
- 10.4 Novo Nordisk
- 10.4.1 Novo Nordisk Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.4.4 Anti-Obesity Therapeutics Product Introduction
- 10.4.5 Novo Nordisk Recent Development
- 10.5 Alizyme
- 10.5.1 Alizyme Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.5.4 Anti-Obesity Therapeutics Product Introduction
- 10.5.5 Alizyme Recent Development
- 10.6 BoehringerIngelheim GmbH
- 10.6.1 BoehringerIngelheim GmbH Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.6.4 Anti-Obesity Therapeutics Product Introduction
- 10.6.5 BoehringerIngelheim GmbH Recent Development
- 10.7 Pfizer
- 10.7.1 Pfizer Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.7.4 Anti-Obesity Therapeutics Product Introduction
- 10.7.5 Pfizer Recent Development
- 10.8 Takeda Pharmaceutical
- 10.8.1 Takeda Pharmaceutical Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.8.4 Anti-Obesity Therapeutics Product Introduction
- 10.8.5 Takeda Pharmaceutical Recent Development
- 10.9 Rhythm Pharmaceuticals
- 10.9.1 Rhythm Pharmaceuticals Company Details
- 10.9.2 Company Description and Business Overview
- 10.9.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.9.4 Anti-Obesity Therapeutics Product Introduction
- 10.9.5 Rhythm Pharmaceuticals Recent Development
- 10.10 Shionogi USA
- 10.10.1 Shionogi USA Company Details
- 10.10.2 Company Description and Business Overview
- 10.10.3 Sales, Revenue and Market Share of Anti-Obesity Therapeutics
- 10.10.4 Anti-Obesity Therapeutics Product Introduction
- 10.10.5 Shionogi USA Recent Development
- 10.11 Vivus
- 10.12 Zafgen
- 10.13 Norgine Pharmaceuticals Ltd.
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Anti-Obesity Therapeutics Sales Channels
- 11.2.2 Anti-Obesity Therapeutics Distributors
- 11.3 Anti-Obesity Therapeutics Customers
12 Market Forecast
- 12.1 Global Anti-Obesity Therapeutics Sales and Revenue Forecast 2019-2025
- 12.2 Global Anti-Obesity Therapeutics Sales Forecast by Type
- 12.3 Global Anti-Obesity Therapeutics Sales Forecast by Application
- 12.4 Anti-Obesity Therapeutics Forecast by Regions
- 12.4.1 Global Anti-Obesity Therapeutics Sales Forecast by Regions 2019-2025
- 12.4.2 Global Anti-Obesity Therapeutics Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Anti-Obesity Therapeutics. Industry analysis & Market Report on Anti-Obesity Therapeutics is a syndicated market report, published as Global (United States, European Union and China) Anti-Obesity Therapeutics Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Anti-Obesity Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
